OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeyondSpring

PetVivo Holdings

Petros Pharmaceuticals

Ring Energy

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy For A Short Squeeze?

Penny Stocks To Buy For A Short Squeeze? 5 To Watch Now

OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.

OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing

ELMWOOD PARK, N.J., Nov. 29, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), announced COVID-19 testing preparedness for the Omicron Variant.

BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.

Cinedigm

IAMGOLD

Are these high volume penny stocks on your watchlist right now? The post 3 Top Penny Stocks With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks With High Volume Right Now

OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.

OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates

OPKO Health Inc (NASDAQ: OPK) reported Q3 revenues were down 10% Y/Y to $385.8 million, beating the consensus of $302.27 million. Revenue from diagnostic services decreased to $340.1 million from $382.5 million, primarily due to a decrease in COVID-19 testing volume, partially offset by an improvement in COVID-19 test reimbursement and an increase in clinical and genomic test revenue.

OPKO Health Q3 Earnings Ahead Of Expectations

OPKO Health's (OPK) CEO Phillip Frost on Q3 2021 Results - Earnings Call Transcript

OPKO Health (OPK) delivered earnings and revenue surprises of 500.00% and 26.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Q3 Earnings and Revenues Top Estimates

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results

MIAMI, Oct. 25, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 28, 2021. OPKO's senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on October 28th beginning at 4:30 p.m. Eastern time.

OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

On Monday, Opko Health Inc. (NASDAQ:OPK) shares edged slightly higher after Jefferies and Piper Sandler analysts issued upbeat statements following Friday's decline. The OPK stock price slipped more than 4% after it announced that the Food and Drug Administration (FDA) had extended the review period for the Biologics License Application (BLA) for Somatrogon.

Should you buy OPKO Health shares? Analysts remain bullish despite the pullback

The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.

OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed

NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD) in pediatric patients. The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to January 2022, as a result of Pfizer's submission of additional data to the original BLA.

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world.

GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

I think OPKO Health is significantly undervalued, specifically Rayaldee, and OPK could be a defensive stock even in a risk off repositioning in global markets.

OPKO Health: A Defensive, Long-Term Holding

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

OPKO Health (OPK) Forms JV, Establishes Presence in China

SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company focused on diagnostics and pharmaceuticals, announce the formation of a joint venture to develop, manufacture and commercialize two of OPKO's clinical stage, long-acting drug products in Greater China and eight other Asian territories.

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories

BioDelivery Sciences

CYREN

Ideanomics Inc

Sonim Technologies Inc

Which Reddit penny stocks are on your watchlist right now? The post Best Reddit Penny Stocks To Buy Now?

Best Reddit Penny Stocks To Buy Now? 5 For Your List In September 2021

MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The U.S. trial, “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of R AYALDEE (calcifediol) E xtended-relea s e C aps u l e s to Treat Symptomatic Patients Infected with SARS-CoV-2 ( REsCue ),” was expected to enroll approximately 160 subjects, including some with stage 3 or 4 chronic kidney disease (CKD) who are at higher risk for developing more severe illness. Final enrollment reached 171 subjects and topline data are expected later this year.

OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients

MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.

OPKO Health to Participate in Two Upcoming Investment Conferences

Rite Aid

CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced a ‘Back to School' COVID-19 testing program offering students at New York State public schools the opportunity for free COVID-19 testing prior to or at the start of the 2021-2022 school year. Students will be tested using highly accurate RT-PCR laboratory-based COVID-19 tests. To participat

Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School' COVID-19 Testing Program

OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.

OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout

ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche.

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

ATI Physical Therapy

Wilhelmina Int.

Are these penny stocks worth watching with the stock market down today? The post Top Penny Stocks to Buy?

Top Penny Stocks to Buy? Why These 3 Should Be on Your Watchlist

Akebia Therapeutics

Seelos Therapeutics

Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for OPKO Health Stock (OPK)